Lauren Shea, MD
Gastroenterology · Boise, IDNPI 1316263601
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,300 of the $6,195 with a category attached, or 85.6%. Capsovision, Inc. accounts for 85.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $4,630 and has fallen 83.8% since, to $750 in 2025.
Across 35 payments — averaging $177.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Capsovision, Inc.$5K
- Medtronic$464
- AbbVie$217
- Intercept Pharmaceuticals, Inc.$48
- Takeda Pharmaceuticals U.S.A., Inc.$48
- Ipsen Biopharmaceuticals, Inc$46
- plus $71 from 4 others
What the payments were for
- Consulting fees$5,30086%
- Travel & lodging$4147%
- Food & beverage$4818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Capsovision, Inc. | 4 | $5,300 |
| Medtronic | 5 | $464 |
| AbbVie | 14 | $217 |
| Intercept Pharmaceuticals, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Ipsen Biopharmaceuticals, Inc | 3 | $46 |
| Amgen | 1 | $23 |
| QOL Medical, LLC | 2 | $22 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CapsoCam Colon$4,600
- CapsoCam Plus$700
- INTERSTIM$300
How this compares
$6,195 in reported general payments places this provider in the 85th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 17 | $461,602 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 142 | $3,450 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,665 |
| Balsalazide Disodium | 13 | $1,325 |
| Sucralfate | 43 | $1,015 |
| Omeprazole | 122 | $854 |
| Esomeprazole Magnesium | 41 | $794 |
| Ondansetron Hcl | 231 | $315 |
| Ondansetron OdtOndansetron | 108 | $212 |
| Pantoprazole Sodium | 18 | $158 |
| Dicyclomine Hcl | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Boise
- Matthew SericatiBoise$111K
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
- Stephen SchutzBoise$5K
- Mark MalloryBoise$4K
- Joseph CookBoise$4K
- Jeffrey BankBoise$4K
- Rebecca OsterkampBoise$3K
- Victor ChenBoise$3K
- Edward KrajicekBoise$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.